Hemophilia Drug Can Cause Complications

January 2006

The off-label usage of a drug that treats bleeding in hemophiliacs has been linked to deaths, strokes, heart attacks, and other complications, according to the Food and Drug Administration (FDA).

NovoSeven was approved by the FDA in 1999 as a clotting drug for use in hemophiliacs. Later the drug showed potential for treating cerebral hemorrhages, a serious stroke that causes bleeding in the brain, but NovoSeven was not approved by the FDA to treat this type of condition.

Novo Nordisk, makers of the drug, say off-label use of NovoSeven has affected older people and those with underlying heart disease. The risk for FDA approved use of the drug for hemophiliacs is said to be low.

For more information about recalled drugs, visit our Dangerous Drug and Recall Legal Center.

Have You Suffered Injuries Due to a Dangerous Drug? Contact Us Now For a Free Evaluation of Your Legal Case.

Call us toll-free at 1-866-943-3427 or get online legal help, and we'll give you a free evaluation of your claim.

Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio, and West Virginia and we associate with experienced attorneys in other states. In addition, all drug-related litigation involves co-counsel.

Source: “Hemophilia Drug Is Linked to Deaths In Off-Label Uses.” The Associated Press. The Wall Street Journal. January 18, 2006.